Luis Alvarez Digitalvision Getty Images
The Food and Drug Administration approved a vaccine on Wednesday Pfizer which protects against adults age 60 and older Respiratory syncytial virusA common pathogen that kills and hospitalized thousands of seniors each year.
Pfizer, in a statement Wednesday, said it expects supplies to be available in the third quarter of this year ahead of the RSV season. The Centers for Disease Control and Prevention’s committee of independent advisers will meet on June 21 to make recommendations on vaccine use.
Pfizer’s approval of the vaccine comes weeks after it was cleared by the FDA Similar shots Targeting is done by RSV GSK.
After decades of failed attempts to develop a vaccine for the virus, the two FDA approvals in just one month represent a historic milestone for public health.
RSV causes mild cold-like symptoms in most people, but older adults are at greater risk of serious illness.
According to the federal Centers for Disease Control and Prevention, the virus kills 6,000 to 10,000 older adults each year and hospitalizes 60,000 to 160,000 of them.
RSV also spreads at the same time as covid and flu.
The combined burden of the three viruses put considerable strain on the health-care system late last year. Two new RSV vaccines from Pfizer and GSK may help ease some of the pressure this fall.
Pfizer’s shot is administered as a single 120-microgram dose.
The vaccine was about 67% effective against lower respiratory tract diseases with at least two signs or symptoms and about 86% effective against these diseases with three signs or symptoms. According to clinical trial results.
The FDA’s committee of independent advisers approved Pfizer’s vaccine in February. However, several members of the panel Dr Security concerns were raised About the shot
Two participants in Pfizer’s clinical trials developed Guillain-Barre syndrome After receiving the vaccine. Guillain-Barré is a rare neurological disorder with symptoms ranging from brief weakness to paralysis.
The FDA considers the two Guillain-Barre cases possibly linked to the vaccine. The agency asked Pfizer to conduct a post-approval safety study to monitor the disorder.
Pfizer has also developed a vaccine for protection newborn From the RSV
FDA advisers supported that shot at a meeting earlier this month. The FDA is expected to make a final decision on that vaccine in August.
Where we collect the information from Source link
Disclaimer:- We include in each post a link to where each content on our website is collected from.If there is a complaint against any post please contact us directly.
Email: post-support.dailyfastnews24.com
You can also write on the popular online news portal dailyfastnews24.com. Writing topics feature, travel, lifestyle, career, IT, agriculture and nature. Send your entry today to [email protected]
advertisement:-If you would like to advertise on our website please contact us here.Our Ads team will contact you very soon.
Email: [email protected]
The cost of advertising:- 1 Post 100 USD Lifetime.
Thank you very much for visiting our website. Have a good day.